Healthy Skepticism Library item: 5685

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: news

Janssen claims “adverse reactions are unlikely”
MaLAM Australian News 1993 Jun

Abstract:

Janssen promotes ketoconazole in Australia for the treatment of pityriasis versicolor but the advertisements do not mention the rare possibility of ketoconazole-induced hepatitis. Other safer products are available for treatment of this condition.

Keywords:
*analysis/Australia/developed countries/ketoconazole/Janssen/ dermatology/safety & risk information/MaLAM/Medical Lobby for Appropriate Marketing/EVALUATION OF PROMOTION: DRUG SAFETY/PROMOTION AND HEALTH NEEDS: PROMOTION IN DEVELOPED COUNTRIES